BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery

Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

2026/02/20 21:46
2 min read

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2025 financial results.

Quanterix will issue a press release regarding its fourth quarter and full year 2025 financial results prior to the conference call on Monday, March 2, 2026, after the market closes. The press release will be posted on the Quanterix website at http://www.quanterix.com/.

To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 7904928.

Interested investors can also access the live webcast from the News & Events page within the Investors section of the Quanterix website at http://www.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.

About Quanterix

Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,000 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.

Contacts

Media
media@quanterix.com

Investor Relations
Joshua Young
ir@quanterix.com

Market Opportunity
4 Logo
4 Price(4)
$0.009101
$0.009101$0.009101
+3.09%
USD
4 (4) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

The Quantum Leap: Preparing for the Next Era of Computational Power

The Quantum Leap: Preparing for the Next Era of Computational Power

While Artificial Intelligence dominated the headlines of the early 2020s, a more fundamental revolution was brewing in the world of Technology: Quantum Computing
Share
Techbullion2026/02/21 05:48
3 Paradoxes of Altcoin Season in September

3 Paradoxes of Altcoin Season in September

The post 3 Paradoxes of Altcoin Season in September appeared on BitcoinEthereumNews.com. Analyses and data indicate that the crypto market is experiencing its most active altcoin season since early 2025, with many altcoins outperforming Bitcoin. However, behind this excitement lies a paradox. Most retail investors remain uneasy as their portfolios show little to no profit. This article outlines the main reasons behind this situation. Altcoin Market Cap Rises but Dominance Shrinks Sponsored TradingView data shows that the TOTAL3 market cap (excluding BTC and ETH) reached a new high of over $1.1 trillion in September. Yet the share of OTHERS (excluding the top 10) has declined since 2022, now standing at just 8%. OTHERS Dominance And TOTAL3 Capitalization. Source: TradingView. In past cycles, such as 2017 and 2021, TOTAL3 and OTHERS.D rose together. That trend reflected capital flowing not only into large-cap altcoins but also into mid-cap and low-cap ones. The current divergence shows that capital is concentrated in stablecoins and a handful of top-10 altcoins such as SOL, XRP, BNB, DOG, HYPE, and LINK. Smaller altcoins receive far less liquidity, making it hard for their prices to return to levels where investors previously bought. This creates a situation where only a few win while most face losses. Retail investors also tend to diversify across many coins instead of adding size to top altcoins. That explains why many portfolios remain stagnant despite a broader market rally. Sponsored “Position sizing is everything. Many people hold 25–30 tokens at once. A 100x on a token that makes up only 1% of your portfolio won’t meaningfully change your life. It’s better to make a few high-conviction bets than to overdiversify,” analyst The DeFi Investor said. Altcoin Index Surges but Investor Sentiment Remains Cautious The Altcoin Season Index from Blockchain Center now stands at 80 points. This indicates that over 80% of the top 50 altcoins outperformed…
Share
BitcoinEthereumNews2025/09/18 01:43
Altcoins Surge as Cryptos Surpass Initial Obstacles

Altcoins Surge as Cryptos Surpass Initial Obstacles

The post Altcoins Surge as Cryptos Surpass Initial Obstacles appeared on BitcoinEthereumNews.com. // Price Reading time: 5 min Published: Feb 20, 2026 at 20:56
Share
BitcoinEthereumNews2026/02/21 06:21